Iatrogenic cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir

Clinical Infectious Diseases

Volumn 47, Issue 12, 2008, Pages

  Ramanathan, Roshan ^a,b   Pau, Alice K ^b   Busse, Kristin H ^c   Zemskova, Marina ^d   Nieman, Lynnette ^d   Kwan, Richard ^b   Hammer, Jean H ^b   Mican, Joann M ^b   Maldarelli, Frank ^e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CORTICOSTEROID; EMTRICITABINE; HYDROCORTISONE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; CASE REPORT; CUSHING SYNDROME; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE BLOOD LEVEL; IATROGENIC DISEASE; LOW BACK PAIN; MALE; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT RESPONSE;

ADULT; CUSHING SYNDROME; DRUG INTERACTIONS; HIV INFECTIONS; HIV-1; HUMANS; IATROGENIC DISEASE; MALE; PYRIMIDINONES; RITONAVIR; TRIAMCINOLONE;

EID: 56749153964     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/593314     Document Type: Article

References (12)

1. Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab 2005; 90:4394-8.
2. Argenti D, Colligon I, Heald D, Ziemniak J. Nasal mucosal inflammation has no effect on the absorption of intranasal triamcinolone acetonide. J Clin Pharmacol 1994; 34:854-8.
3. Derendorf H, Möllmann H, Grüner A, Haack D, Gyselby G. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther 1986; 39:313-7.
4. Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J. Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. J Acquir Immune Defic Syndr 2005; 40:573-80.
5. Weemhoff J, Von Moltke L, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ. Apparent mechanism-based inhibition of human CYP3A in vitro by lopinavir. J Pharm Pharmacol 2003; 55:381-6.
6. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 2005; 33:764-70.
7. Horiike N, Abe M, Kumagi T, et al. The quantification of cytochrome P-450 (CYP 3A4) mRNA in the blood of patients with viral liver diseases. Clin Biochem 2005; 38:531-4.
8. Horani MH, Silverberg AB. Secondary Cushing's syndrome after a single epidural injection of corticosteroid. Endocr Pract 2005; 11:408-10.
9. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001; 40:893-905.
10. Jinno S, Goshima C. Progression of Kaposi's sarcoma associated with iatrogenic Cushing's syndrome in a person with HIV/AIDS. AIDS Read 2008; 18:100-4.
11. Fauci AS. Mechanism of corticosteroid action on lymphocyte subpopulations. Clin Exp Immunol 1976; 24:54-62.
12. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29:687-710.